ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab
Janssen
['dara ', 'cilta-cel', 'cartitude-4', 'bortezomib', 'mmsm', 'borte', 'cartitude']
 cartitude-4 first data: a 1st randomized trial of cilta-cel for myeloma
- all len-refractory, med prior lines 2, 30% only 1 prior line
- 20% dara refr, ~25% bortezomib-refr, 15% triple class refr
- 32 pts (15%) progressed/died before cilta-cel could be given
#asco23 #mmsm 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem